RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
RBC Capital has maintained its Outperform rating for Aptose Biosciences (NASDAQ:APTO) but lowered its price target from $40.00 to $23.00. Aptose Biosciences' shares are currently trading up 6.98% at $4.28 per share. A move to $23.00 would represent a 437.46% increase from the current share price.
August 11, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital's maintained Outperform rating and lowered price target could influence investor sentiment and trading behavior, potentially impacting Aptose Biosciences' stock price.
Analyst ratings and price targets can significantly influence investor sentiment and trading behavior. While the maintained Outperform rating is positive, the lowered price target could create some uncertainty, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100